{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:23:47Z","timestamp":1768346627288,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ejca.2022.01.025","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T17:05:55Z","timestamp":1645895155000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer"],"prefix":"10.1016","volume":"165","author":[{"given":"Carlotta","family":"Antoniotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Marmorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-4396","authenticated-orcid":false,"given":"Alessandra","family":"Boccaccino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-5230","authenticated-orcid":false,"given":"Silvia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Antista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Zuco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-469X","authenticated-orcid":false,"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-4005","authenticated-orcid":false,"given":"Veronica","family":"Conca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Zucchelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Borelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco M.","family":"Germani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria F.","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-2517","authenticated-orcid":false,"given":"Martina","family":"Carullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-2897","authenticated-orcid":false,"given":"Guglielmo","family":"Vetere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-9269","authenticated-orcid":false,"given":"Roberto","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-8989","authenticated-orcid":false,"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.01.025_bib1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JGO.19.00367","article-title":"Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline","author":"Chiorean","year":"2020","journal-title":"J Clin Oncol Global Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumour activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.01.025_bib4","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3892\/or.2014.3487","article-title":"Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumour activity in mouse models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2022.01.025_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.01.025_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.01.025_bib8","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study","author":"Xu","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000495","article-title":"Maximising clinical benefit with adequate patient management beyond the second line in mCRC","volume":"4","author":"Argiles","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.01.025_bib10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/bjc.2011.85","article-title":"Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer","volume":"104","author":"Loupakis","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.01.025_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/cancers12051330","article-title":"From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): circulating predictive biomarkers to anti-VEGFR therapy","volume":"12","author":"Giampieri","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.01.025_bib13","doi-asserted-by":"crossref","first-page":"34811","DOI":"10.18632\/oncotarget.9187","article-title":"Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer","volume":"7","author":"Suenaga","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.01.025_bib14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/jco.2016.34.4_suppl.672","article-title":"Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC)","volume":"34","author":"Teufel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib17","doi-asserted-by":"crossref","first-page":"iv135","DOI":"10.1093\/annonc\/mdz154.025","article-title":"Results of REARRANGE trial: a randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"30","author":"Argiles","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.01.025_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.bjc.6605483","article-title":"Biomarkers of angiogenesis and their role in the development of VEGF inhibitors","volume":"102","author":"Murukesh","year":"2010","journal-title":"Br J Cancer"},{"issue":"Pt 4","key":"10.1016\/j.ejca.2022.01.025_bib19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1242\/jcs.01653","article-title":"The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism","volume":"118","author":"Scharpfenecker","year":"2005","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1016\/j.ejca.2022.01.025_bib20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.2011.38.7621","article-title":"Targeting the angiopoietin\/Tie2 pathway: cutting tumour vessels with a double-edged sword?","volume":"30","author":"Cascone","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.01.025_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/sj.bjc.6605925","article-title":"Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy","volume":"103","author":"Goede","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.01.025_bib22","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/0008-5472.CAN-12-4697","article-title":"Angiopoietin-2: an attractive target for improved antiangiogenic tumour therapy","volume":"73","author":"Gerald","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.01.025_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12029-020-00392-1","article-title":"Angiopoietin-2 as a prognostic factor in patients with incurable stage IV colorectal cancer","volume":"52","author":"Munakata","year":"2021","journal-title":"J Gastrointest Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.01.025_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/annonc\/mdw627","article-title":"Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram","volume":"28","author":"Pietrantonio","year":"2017","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:33Z","timestamp":1760733333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":24,"alternative-id":["S0959804922000582"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}